Results 41 to 50 of about 6,560 (205)
Molnupiravir: A new candidate for COVID‐19 treatment [PDF]
Pharmacology Research & Perspectives, 2021 AbstractThe novel coronavirus disease 2019 (COVID‐19) emerged in late December 2019 in china and has rapidly spread to many countries around the world. The effective pharmacotherapy can reduce the mortality of COVID‐19. Antiviral medications are the candidate therapies for the management of COVID‐19.
Fariba Pourkarim +2 more
openaire +3 more sources
Aging and Health Research, 2023 Background: Molnupiravir is being widely used as a treatment for coronavirus disease 2019 (COVID-19); however, its acceptability and safety in older patients aged ≥ 80 years in real-world clinical practice is not well understood.
Kohei Fujita +8 more
doaj +1 more source
Use of molnupiravir: A Danish nationwide drug utilization study [PDF]
, 2023 Purpose: To describe utilization patterns, characteristics of users and prescribers of the new oral antiviral medication, molnupiravir, indicated for mild-to-moderate COVID-19.
Jesper Hallas +13 more
core +1 more source
Molnupiravir—A Novel Oral Anti-SARS-CoV-2 Agent
Antibiotics, 2021 Since December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly resulted in a global pandemic with approximately 4 million deaths.
Ching-Chi Lee +2 more
doaj +1 more source
, 2022 Molnupiravir (Lagevrio®) is an orally-administered anti-COVID-19 agent. Due to the urgency to meet the worldwide demand and the growing environmental concern, there is a need for speed in the industrial implementation of novel and efficient bioprocesses ...
Del Arco, Jon +11 more
core +1 more source
Antiviral activity of molnupiravir against COVID-19: a schematic review of evidences
Bulletin of the National Research Centre, 2022 Background The study was aimed at encapsulating the evidence of in vitro and in vivo antiviral activities of molnupiravir and its active form against highly pathogenic SARS-CoV-2, the pathogen responsible for COVID-19, and finding out the efficacy and ...
Shivali Singla, Sachin Goyal
doaj +1 more source
Molnupiravir in unvaccinated patients with COVID-19 [PDF]
Drug and Therapeutics Bulletin, 2022 Abstract Overview of: Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients. NEJM. 2021;doi:10.1056/NEJMoa2116044 [Epub ahead of print 16 Dec 2021].
openaire +2 more sources
Progress Towards a Large-Scale Synthesis of Molnupiravir (MK-4482, EIDD-2801) from Cytidine
, 2021 Molnupiravir (MK-4482, EIDD-2801) is a promising orally bioavailable drug candidate for treatment of COVID-19. Herein we describe a supply-centered and chromatography-free synthesis of molnupiravir from cytidine, consisting of two steps: a
Catherine P., McGeough +8 more
core +1 more source
The Lancet Regional Health. Western Pacific, 2023 Summary: Background: Real-world data is currently limited on the association between oral antiviral therapy and healthcare system burden in patients with mild-to-moderate COVID-19.
Abraham Ka-Chung Wai +15 more
doaj +1 more source
, 2021 Title from PDF caption (viewed on January 4, 2022)."OHA4029A12292021 CHUUKESE"--Running footer.This archived document is maintained by the State Library of Oregon as part of the Oregon Documents Depository Program.
core